April 13, 2026 – Eqwires | Stock Market Advisory

The Indian equity markets staged a strong comeback on Friday, April 10, 2026, as the nifty share price surged alongside benchmark indices, signaling renewed investor confidence. In today’s share market news, the BSE Sensex rallied 918.60 points (1.20%) to close at 77,550.25, while the NSE nifty 50 reclaimed the crucial 24,000 mark, ending at 24,050.50 with gains of 275.40 points (1.16%).

This sharp rebound reflects a broad-based recovery in the stock market today, driven by easing global tensions and strong buying across key sectors.

Why Nifty Share Price Rose in Stock Market Today

The primary driver behind the surge in the nifty share price was improving global sentiment. Optimism surrounding US-Iran ceasefire talks helped stabilize crude oil prices, which had earlier weighed heavily on market sentiment.

Lower oil prices eased concerns around inflation and trade balance, supporting emerging markets like India. This shift boosted investor confidence and triggered buying across sectors, contributing to a strong market rally today.

Banking and Auto Stocks Lead Market Rally Today

Banking Sector Strength

High-weightage banking stocks led the rally, with strong buying seen after weeks of selling pressure by foreign institutional investors. ICICI Bank was among the top contributors, supporting gains in sensex news and lifting overall market sentiment.

Auto Sector Momentum

Auto stocks also showed strong momentum, backed by solid March sales data and product innovation. Eicher Motors gained traction after unveiling its first electric motorcycle, helping the sector post notable gains.

Top Gainers and Losers in Sensex News Today

The broader market remained positive, with mid-cap and small-cap indices rising nearly 1% each.

Top Gainers

Asian Paints (+3.81%)
Eicher Motors (+3.75%)
Bajaj Auto (+3.29%)
ICICI Bank (+3.24%)
M&M (+3.13%)

Top Losers

Coal India (-4.14%)
Sun Pharmaceutical Industries (-3.62%)
Infosys (-3.02%)
Tata Consultancy Services (-2.55%)
Tech Mahindra (-1.55%)

While most sectors advanced, IT stocks lagged due to earnings concerns and global demand uncertainties.

Nifty Crosses 24000 Mark with Strong Momentum

A key highlight of the session was when the nifty crosses 24000 level, a major psychological milestone for investors. The rise in the nifty share price was supported by strong sectoral performance, easing crude oil prices, and a stable currency outlook.

The resilience of the Indian rupee against the US dollar also contributed to positive sentiment, reducing pressure on import-heavy sectors and boosting overall confidence in the stock market today.

Outlook for Nifty 50 After Friday Rebound Rally

Looking ahead, market participants will closely monitor global developments and domestic economic indicators. The ability of the nifty 50 to sustain above the 24,000 mark will be crucial for further upside.

Analysts suggest that if momentum continues, the next resistance level could be around 24,400. However, caution remains due to:

Volatile foreign institutional investor (FII) activity
Upcoming inflation data
Global geopolitical uncertainty

The latest share market news suggests that while sentiment has improved, markets may remain sensitive to external triggers.

Stock Market Today Shows Signs of Strong Recovery Trend

The strong recovery in the stock market today has provided relief to investors after recent volatility. The surge in nifty share price and gains reflected in sensex news indicate renewed confidence in Indian equities.

With improving global cues and sectoral strength, the market appears to be stabilizing. However, sustained momentum will depend on macroeconomic stability and consistent investor participation in the coming sessions.

Eqwires Research Analyst

Top-notch SEBI registered research analyst

Best SEBI registered Intraday tips provider

info@eqwires.com

Telegram | Facebook | Instagram

Call: +91 9624421555 / +91 9624461555

www.eqwires.com

The Indian pharmaceutical landscape witnessed a seismic shift today as shares of Sun Pharmaceutical Industries, the nation’s largest drugmaker, tumbled nearly 4.1% to hit a low of ₹1,646.50 on the NSE. This sharp decline has quickly become a major highlight in sun pharma news, as investors react to the ongoing sun pharma organon acquisition developments.

The sharp decline comes amidst intensifying reports that Sun Pharma is in the final stages of submitting a massive $12 billion (approx. ₹1 lakh crore) binding offer to acquire Organon & Co.. If finalised, the deal would represent the largest overseas acquisition ever attempted by an Indian pharmaceutical company, dwarfing Sun Pharma’s own previous records. However, the sheer scale of the transaction has sparked a wave of investor anxiety regarding the company’s balance sheet and the potential for significant debt accumulation.

Deal Details Behind Sun Pharma Acquisition Strategy

Sun Pharma has reportedly spent the last three months conducting rigorous due diligence on Organon, a company spun off from Merck (MSD) in 2021. The sun pharma acquisition is viewed as a strategic masterstroke by Chairman Dilip Shanghvi to pivot Sun Pharma from a generics leader into a global powerhouse in branded and innovative medicines, particularly in women’s health and biosimilars.

Financing Plans Supporting Sun Pharma Acquisition Strategy

Sun Pharma is reportedly assembling an all-cash offer backed by a consortium of global heavyweights, including JPMorgan, MUFG, Standard Chartered, and Citi. This financing structure is being closely tracked in sun pharma news, as investors assess how the company plans to execute the deal without significantly straining its balance sheet.

Debt Concerns Impacting Sun Pharma Share Performance

While Sun Pharma boasts a healthy cash reserve of approximately $3.2 billion, acquiring Organon means inheriting its massive $8 billion debt load. Investors fear this could spike Sun’s net debt-to-EBITDA ratio to levels not seen in years, putting additional pressure on sun pharma share performance in the short term.

Growth Versus Risk in Organon Acquisition Deal

Sales of Organon’s primary product, the contraceptive implant Nexplanon, have recently declined, and the business has had governance issues, such as the CEO’s departure in late 2025. As investors balance long-term growth potential against execution risks and integration issues, these variables complicate the Sun Pharma Organon acquisition.

Market Reaction to Sun Pharma Share Price Movement

Despite the long-term potential for higher margins through innovative drugs, the market is currently prioritising risk assessment. Analysts point out that integrating a debt-ridden global entity like Organon, which has seen its own stock price collapse by over 55% in the last 18 months, is a “Herculean task.”

The decline in sun pharma share value also coincides with a broader sector cooling, as new US reciprocal tariffs on Indian goods and rising input costs add a layer of macroeconomic uncertainty.

Expert Insights From Latest Sun Pharma News Analysis

In a market where a single headline can swing a stock by 5%, having expert guidance is non-negotiable. Eqwires stands as the Best SEBI-Registered Research Analyst in India, offering traders and investors the precision they need.

Whether you are looking for Intraday Trading Tips & Calls by Eqwires Experts or high-conviction Equity Stock Recommendations & Strategies, Eqwires provides data-driven insights. They specialise in Index & Nifty Trading Advisory and sophisticated Options & F&O Trading Strategies designed for today’s dynamic environment.

For those seeking short-term gains, their BTST (Buy Today Sell Tomorrow) Calls and Swing Trading Ideas & Profitable Strategies are industry-leading. As a Top Stock Market Advisory Services in India, Eqwires is committed to delivering High-Accuracy Market Predictions & Investment Tips alongside Trusted Stock Market Education & Trading Insights to empower your financial journey.

Technical Outlook for Sun Pharma Share Support Levels

Sun Pharma may be testing its 200-day moving average right now, according to technical analysts. The stock may continue to decline toward its 52-week low of ₹1,480 if it is unable to maintain the ₹1,640 level.According to a prominent healthcare analyst at a brokerage in Mumbai, “the market is pushing Dilip Shanghvi to demonstrate that this is not simply a drive for size but a road to sustainable profitability.” “We anticipate that the stock will continue to be under pressure until Organon’s financial structure and turnaround plan are revealed.”

What Investors Should Watch in Coming Weeks Ahead

Market participants will keep a careful eye on developments regarding the Sun Pharma Organon purchase going ahead, especially with regard to deal financing, regulatory approvals, and integration plan. Any clarity on these fronts might have a big impact on stock performance and investor mood.